1. Home
  2. CAAS vs SPRO Comparison

CAAS vs SPRO Comparison

Compare CAAS & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CAAS

China Automotive Systems Inc.

HOLD

Current Price

$4.52

Market Cap

130.6M

ML Signal

HOLD

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$2.57

Market Cap

136.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CAAS
SPRO
Founded
N/A
2013
Country
China
United States
Employees
N/A
N/A
Industry
Auto Parts:O.E.M.
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
130.6M
136.7M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
CAAS
SPRO
Price
$4.52
$2.57
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$5.00
AVG Volume (30 Days)
22.7K
261.3K
Earning Date
11-12-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
5.68
N/A
EPS
1.11
N/A
Revenue
$725,260,000.00
$40,549,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$4.04
N/A
Revenue Growth
16.72
N/A
52 Week Low
$3.50
$0.51
52 Week High
$5.37
$3.22

Technical Indicators

Market Signals
Indicator
CAAS
SPRO
Relative Strength Index (RSI) 68.95 65.92
Support Level $4.24 $2.26
Resistance Level $4.60 $2.66
Average True Range (ATR) 0.13 0.09
MACD 0.03 0.03
Stochastic Oscillator 93.33 76.68

Price Performance

Historical Comparison
CAAS
SPRO

About CAAS China Automotive Systems Inc.

China Automotive Systems Inc is a holding company. The firm through its subsidiary is a supplier of power steering systems and components to China's automotive industry. Its product offering encompasses a full range of auto parts incorporated into steering systems for both passenger automobiles and commercial vehicles. The company offers four separate series, models of power steering including rack and pinion power steering, integral power steering, electronic power steering and manual steering, steering columns, steering oil pumps, and steering hoses. Geographically, it derives a majority of its revenue from China.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: